Celldex Therapeutics, Inc. (CLDX)
27.53
-1.40
(-4.84%)
USD |
NASDAQ |
Oct 16, 16:00
27.53
0.00 (0.00%)
After-Hours: 18:28
Celldex Therapeutics Enterprise Value : 1.565B for Oct. 15, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 15, 2026 | 1.565B |
| October 14, 2026 | 1.479B |
| October 13, 2026 | 1.511B |
| October 12, 2026 | 1.604B |
| October 09, 2026 | 1.640B |
| October 08, 2026 | 1.594B |
| October 07, 2026 | 1.682B |
| October 06, 2026 | 1.728B |
| October 05, 2026 | 1.852B |
| October 02, 2026 | 1.778B |
| October 01, 2026 | 1.820B |
| September 30, 2026 | 1.838B |
| September 29, 2026 | 1.777B |
| September 28, 2026 | 1.766B |
| September 25, 2026 | 1.735B |
| September 24, 2026 | 1.765B |
| September 23, 2026 | 1.737B |
| September 22, 2026 | 1.924B |
| September 21, 2026 | 2.268B |
| September 18, 2026 | 2.295B |
| September 17, 2026 | 2.354B |
| September 16, 2026 | 2.332B |
| September 15, 2026 | 2.317B |
| September 14, 2026 | 2.369B |
| September 11, 2026 | 2.190B |
| Date | Value |
|---|---|
| September 10, 2026 | 2.284B |
| September 09, 2026 | 2.338B |
| September 08, 2026 | 2.365B |
| September 04, 2026 | 2.409B |
| September 03, 2026 | 2.384B |
| September 02, 2026 | 2.393B |
| September 01, 2026 | 2.374B |
| August 31, 2026 | 2.405B |
| August 28, 2026 | 2.365B |
| August 27, 2026 | 2.470B |
| August 26, 2026 | 2.478B |
| August 25, 2026 | 2.529B |
| August 24, 2026 | 2.478B |
| August 21, 2026 | 2.463B |
| August 20, 2026 | 2.429B |
| August 19, 2026 | 2.567B |
| August 18, 2026 | 2.574B |
| August 17, 2026 | 2.584B |
| August 14, 2026 | 2.587B |
| August 13, 2026 | 2.639B |
| August 12, 2026 | 2.816B |
| August 11, 2026 | 2.774B |
| August 10, 2026 | 2.667B |
| August 07, 2026 | 2.568B |
| August 06, 2026 | 2.556B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 216.58B |
| ACADIA Pharmaceuticals, Inc. | 2.510B |
| Alnylam Pharmaceuticals, Inc. | 30.98B |
| Anika Therapeutics, Inc. | 263.73M |
| Savara, Inc. | 830.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.50M |
| Revenue (Quarterly) | 0.022M |
| Total Expenses (Quarterly) | 73.52M |
| EPS Diluted (Quarterly) | -0.9443 |
| Gross Profit Margin (Quarterly) | -4.00K% |
| Profit Margin (Quarterly) | -334.1K% |
| Earnings Yield | -15.83% |
| Normalized Earnings Yield | -15.83 |